Access read Alzheimer’s has not had a diagnosis problem for several years. It has had a queue problem. Confirming amyloid pathology, which the new antibody therapies require before treatment, has meant PET imaging or lumbar puncture, both specialist-only, both rationed, both slow. Patients wait to be confirmed, and a proportion progress past the window in which the drugs are worth giving while they wait. That is the real constraint on the anti-amyloid class, and no amount of prescribing enthusiasm fixes it. Which is why the location of this study matters more than the technology. Putting an accurate blood test in front of the referral rather than behind it changes the shape of the funnel: general practitioners can triage before sending anyone on, so specialist clinics see enriched populations instead of everyone, and the queue shortens without anyone building a scanner. One of the Imperial investigators puts the current position plainly, describing general practice as operating in a grey area, responding to patient concerns without precise tools. Note the two-track commercial strategy running underneath. In the UK, C2N is generating the pathway evidence a public system needs before it adopts anything at scale. In the US, it has secured a first payer decision effective October. Two systems, two routes to the same destination, and the diagnostic reaching routine use is the event that finally makes the treatments usable.